Tracking dry age-related macular degeneration with eye scans and artificial intelligence
Follows people with atrophic macular degeneration using eye scans and AI to track progression.
Plain-language title generated from the registry record
Registry title: Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
Key facts
- Where
- Vienna, AustriaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 55 to 99 with atrophic age-related macular degeneration (geographic atrophy) that is away from the centre of the retina and has not yet harmed vision. They are followed for 24 months with eye scans.
- Age
- 55 to 99 years
- Sex
- All sexes
- Disease stage
- Complete RPE and outer retinal atrophy (cRORA) in the eye: a region of at least 250 µm in diameter with light passing through more than normal, and a damaged RPE zone of at least 250 µm in diameter. Photoreceptors above it show degeneration. No scrolled RPE or RPE tear. Both eyes can join if both qualify.
- Earlier treatment
- No anti-VEGF treatment in the study eye before the start. No eye surgery in the study eye in the 3 months before the start.
Main reasons for not taking part
- Active macular neovascularization at the start
- History of anti-VEGF treatment in the study eye
- History of pseudophakic cystoid macular edema (Irvine Gass Syndrome) in the study eye
- Uncontrolled glaucoma in the study eye, or C/D Ratio > 0.9
- Refractive error larger than 6 diopters, or taking drugs known to cause retinal toxicity such as hydroxychloroquine or tamoxifen
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 99 years old?
Source: NCT06351657, who can take part
Where in Austria
- Medical University of ViennaVienna, AustriaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Medical University of Vienna
- Trial code
- NCT06351657
- Record updated
- 15 May 2025
- Original description
The goal of this prospective, multinational, multicenter observational study is to assess and predict progression in non-foveal, non-vision compromising atrophic AMD on an individual-based level over two years. The main objectives of this study are:Read full original descriptionShow less
Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression in a Prospective, Multinational, Multicenter Observational Study
The goal of this prospective, multinational, multicenter observational study is to assess and predict progression in non-foveal, non-vision compromising atrophic AMD on an individual-based level over two years. The main objectives of this study are:
* Assess the individual progression rate of a patient in non-foveal, non-vision compromising atrophic AMD and assess personalized risk of progression based on imaging. * Identify and quantify focal and global alterations in the retina in regard to disease progression. * Evaluate the monitoring of AMD progression using approved AI algorithms.
All patients will be followed for 24 months with 6 month intervals to assess clinical changes. Monitoring of disease progression will be performed using the following routine in-vivo imaging procedures:
* Scanning Laser Fundus Photography * Color Fundus Photography (CFP) * Optical Coherence Tomography (OCT) * Optical Coherence Tomography Angiography (OCTA)
Patients will be asked for their medical history. Standard ophthalmic examination, as well as a questionnaire on visual function will be carried out.
No intervention will be performed during the study since no treatment is yet available within Europe. As soon as treatment is approved in the EU, patients in this cohort might receive treatment according to availability in their respective country and standard of care. If treatment will be performed, it will be as standard of care outside the study according to each country's standard of care and by EMA label.
Inclusion: Age: 55-99 years old; Complete RPE and outer retinal atrophy (cRORA). This is (1) a region of hypertransmission of at least 250 µm in diameter, (2) a zone of attenuation or disruption of the RPE of at least 250 µm in diameter, (3) evidence of overlying photoreceptor degeneration, and (4) absence of scrolled RPE or other signs of an RPE tear; If both eyes are eligible, both eyes will be included in the cohort study; Clear optical media and adequate pupillary dilation for imaging and functional testin.
Exclusion: Any surgical treatment of the eye within 3 months prior to baseline in the study eye; History of uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) ≥ 25 mmHg despite treatment with IOP lowering medication), or C/D Ratio > 0.9; Any concurrent intraocular condition in the study eye (e.g. advanced cataract or moderate/severe diabetic retinopathy) that, in the opinion of the investigator, will most likely require medical or surgical intervention during the study period to prevent or treat visual loss that might result from that condition; Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could cause an unwanted effect on treatment efficacy, compliance or require intraocular surgery (except for cataract surgery and YAG capsulotomy) during the study period; Intake of drugs known to cause retinal toxicity (e.g. hydroxychloroquine or tamoxifen); History of anti-VEGF treatment in the study eye before baseline; History of pseudophakic cystoid macular edema (Irvine Gass Syndrome) in the study eye; Refractive error larger than 6 diopters. In case of pseudophakia or refractive surgery: History of refractive error larger than 6 diopters; Presence of corneal decompensation, haze or scarring with an impact on BCVA; Presence of active macular neovascularization at baseline.